Literature DB >> 30684216

A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody.

Johannes J Roggenbuck1, Miklos Veiczi2, Karsten Conrad3, Peter Schierack4, Gerd Wunderlich1, Joerg Kotzerke1, Dirk Roggenbuck2,4, Klaus Zöphel5.   

Abstract

TSH receptor (TSHR) autoantibody (TRAb) is the serological hallmark of Graves' disease (GD). Third-generation enzyme-linked immunosorbent assays (ELISAs) using monoclonal TRAbs instead of TSH have been found useful for TRAb analysis recently. For the first time, a mouse monoclonal antibody (mAb) against TSHR was analyzed for TRAb detection and compared with human mAb M22 and TSH by the same competitive binding assay technique. A mouse monoclonal antibody (T7) binding to the TSH receptor and inhibiting TSH binding was generated and used for TRAb analysis in a third-generation ELISA. Obtained TRAb levels were compared with a second-generation TRAb assay employing bovine TSH and a third-generation assay with human mAb M22 as TSHR-binding reagents by investigating 89 patients with GD, 56 with Hashimoto's thyroiditis (HT), 73 with non-autoimmune thyroid diseases, 17 with rheumatoid arthritis, and 100 healthy subjects. The T7-based TRAb ELISA did not reveal a significantly different assay performance (area under the curve [AUC]) in contrast to the TSH and M22-based TRAb ELISAs by receiver operating characteristic (ROC) curve analysis (AUC-T7 0.967, AUC-TSH 0.972, AUC-M22 0.958, p > 0.05, respectively). After adjustment of cutoffs by ROC, all three TRAb ELISAs demonstrated sensitivities and specificities above 89.9% and 96.0%, respectively. Both third-generation TRAb ELISAs showed a tendency for a higher prevalence of TRAb positives in HT in contrast to the second-generation ELISA. Mouse mAbs against the TSHR may be used for the reliable detection of TRAb by third-generation TRAb ELISA. The earlier reported higher sensitivity of third-generation TRAb ELISA in GD needs to be considered in the context of a slightly lower specificity regarding HT.

Entities:  

Keywords:  Autoantibodies; Graves’ disease; Hashimoto’s thyroiditis; TSH receptor; Thyroid

Mesh:

Substances:

Year:  2018        PMID: 30684216     DOI: 10.1007/s12026-018-9062-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  34 in total

1.  Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA.

Authors:  J Bolton; J Sanders; Y Oda; C Chapman; R Konno; J Furmaniak; B Rees Smith
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

2.  Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays.

Authors:  K Zöphel; D Roggenbuck; G Wunderlich; M Schott
Journal:  Horm Metab Res       Date:  2010-10-05       Impact factor: 2.936

Review 3.  Clinical review about TRAb assay's history.

Authors:  Klaus Zöphel; Dirk Roggenbuck; Matthias Schott
Journal:  Autoimmun Rev       Date:  2010-06-04       Impact factor: 9.754

Review 4.  The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.

Authors:  B Rapoport; G D Chazenbalk; J C Jaume; S M McLachlan
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

5.  Clinical Evaluation of the First Automated Assay for the Detection of Stimulating TSH Receptor Autoantibodies.

Authors:  S Allelein; M Ehlers; S Goretzki; D Hermsen; J Feldkamp; M Haase; T Dringenberg; C Schmid; H Hautzel; M Schott
Journal:  Horm Metab Res       Date:  2016-12-06       Impact factor: 2.936

Review 6.  Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis.

Authors:  Tristan Struja; Hannah Fehlberg; Alexander Kutz; Larissa Guebelin; Christian Degen; Beat Mueller; Philipp Schuetz
Journal:  Eur J Endocrinol       Date:  2016-10-25       Impact factor: 6.664

7.  TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor.

Authors:  Keiichi Kamijo
Journal:  Endocr J       Date:  2003-02       Impact factor: 2.349

8.  An improved radioreceptor assay for TSH receptor antibodies.

Authors:  G Shewring; B R Smith
Journal:  Clin Endocrinol (Oxf)       Date:  1982-10       Impact factor: 3.478

9.  Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule.

Authors:  N Shimojo; Y Kohno; K Yamaguchi; S Kikuoka; A Hoshioka; H Niimi; A Hirai; Y Tamura; Y Saito; L D Kohn; K Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  TSH Receptor Antibody Functionality and Nomenclature.

Authors:  George J Kahaly; Tanja Diana
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-15       Impact factor: 5.555

View more
  4 in total

1.  Editorial: autoimmunity-the ever endless world.

Authors:  Elias Toubi
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

2.  Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) - one step less, similar results?

Authors:  Johannes J Roggenbuck; Grit Zarske; Peter Schierack; Gerd Wunderlich; Karsten Conrad; Joerg Kotzerke; Dirk Roggenbuck; Klaus Zöphel
Journal:  Nuklearmedizin       Date:  2021-02-03       Impact factor: 1.379

3.  The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.

Authors:  Ya Fang; Wen-Hua Du; Cao-Xu Zhang; Shuang-Xia Zhao; Huai-Dong Song; Guan-Qi Gao; Mei Dong
Journal:  BMC Endocr Disord       Date:  2021-11-30       Impact factor: 2.763

4.  Comparative performance of ELISA and dot blot assay for TSH-receptor antibody detection in Graves' disease.

Authors:  Zulkarnain Zulkarnain; Zulvikar Syambani Ulhaq; Hidayat Sujuti; Djoko Wahono Soeatmadji; Hendra Zufry; Dyah Kinasih Wuragil; Agung Pramana W Marhendra; Wibi Riawan; Siti Kurniawati; Yudit Oktanella; Aulanni'am Aulanni'am
Journal:  J Clin Lab Anal       Date:  2022-02-20       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.